

GLAXOSMITHKLINE PLC  
Form 6-K  
October 11, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending October 2012

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

The Administrators of the Deferred Investment Award Programme notified the Company and the under-mentioned persons on 10 October 2012 of the following increases in their notional interests in Ordinary Shares at a price of 1460.25 pence per Share following the re-investment of the dividend paid to shareholders on 4 October 2012.

|                      |         |
|----------------------|---------|
| Mr S A Hussain       | 294.615 |
| Mr D S Redfern       | 130.074 |
| Ms C Thomas          | 81.296  |
| Dr P J T<br>Vallance | 62.890  |
| Ms E Walmsley        | 605.748 |
| Mr C Weber           | 83.333  |
| Mrs V A Whyte        | 160.660 |

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte  
Company Secretary

11 October 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: October 11, 2012

By: VICTORIA WHYTE  
-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc